Myriad Genetics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Myriad Genetics Inc's ROI in the second quarter of 2026?
Myriad Genetics Inc recorded a cumulative net loss of $-113 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -20.43%.

Within the Healthcare sector 193 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3822 to 3881.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-29.41 %	-39.31 %	-32.67 %	-27.3 %	-18.48 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	508	544	573	580	477
Return On Investment (TTM)	-20.43 %	-73.59 %	-58.89 %	-57.71 %	-50.62 %
MYGN's Overall Ranking	# 3881	# 3822	# 1404	# 3532	# 3053
Seq. Investment Change TTM	1.42 %	-12.53 %	-10.47 %	-11.11 %	-12.81 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-113	-400	-366	-401	-395

MYGN Company Profile >> Back to MYGN Roi Comparisons >> See Annual MYGN Return On Investment

Return On Investment MYGN's Ranking
Within:	No.
Industry	# 4
Sector	# 194
Overall	# 3881

Return On Investment Statistics
High	Average	Low
27.22 %	-4.4 %	-73.59 %
(Dec 31 2013)		(Mar 31 2026)

News about Myriad Genetics Inc Return on Investment ROI

Myriad Genetics Appoints Renowned Physician to Lead Women's Health Division Amidst Company Challenges

February 15, 2024

In a move aimed at bolstering its position in the field of genetic testing and precision medicine, Myriad Genetics, Inc. (NASDAQ: MYGN) has appointed esteemed physician Dr. Dallas Reed as the Principal Medical Advisor to its women s health business unit. Effective immediately, Dr. Reed s appointment is seen as a strategic decision by the company to navigate through the challenges it has been facing.
Myriad Genetics, a leading player in the genetic testing industry, has witnessed a dip in its share value with a 1.8% decrease recorded in February 2024. This decline comes as the company s cumulative net loss for the 12-month period ending in the third quarter of 2023 amounted to a staggering $-274 million. Consequently, Myriad Genetics reported a negative return on investment (ROI) of -27.49%.

Financial Statements
Myriad Genetics Inc's II. Quarter Investments	$ 508 Millions	MYGN's Balance sheet
Myriad Genetics Inc's II. Quarter Income	$ -43 Millions	Quarterly MYGN's Income Statement
MYGN's Income by Division		See MYGN's Income by Division

MYGN Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	573	864	991	1,062	1,116
Y / Y Investment Growth	-33.67 %	-12.83 %	-6.68 %	-4.92 %	-11.23 %
Net Income in Millions	-366	-127	-263	-112	-27
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-63.88 %	-14.74 %	-26.58 %	-10.55 %	-2.44 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
MYGN's Roi Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for MYGN's Competitors
Subscribers only: Roi for Myriad Genetics Inc's Suppliers
Subscribers only: Return On Investment for MYGN's Customers

Other Ratios
MYGN's Roa	MYGN's Inventory Turnover Ratio	MYGN's Growth Rates	MYGN's Dividend Statistics
	MYGN's Profitability Ratios	MYGN's Asset Turnover Ratio	MYGN's Dividend Growth
MYGN's Roe	MYGN's Valuation Ratios	MYGN's Financial Strength Ratios	MYGN's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T06:55:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.